Avasopasem manganese (GC4419) protects against cisplatin-induced chronic kidney disease: An exploratory analysis of renal metrics from a randomized phase 2b clinical trial in head and neck cancer patients

[1]  C. Ross,et al.  Acute kidney injury during cisplatin therapy and associations with kidney outcomes 2 to 6 months post-cisplatin in children: a multi-centre, prospective observational study , 2022, Pediatric Nephrology.

[2]  J. Buatti,et al.  Mitochondrial Superoxide Dismutase in Cisplatin-Induced Kidney Injury , 2021, Antioxidants.

[3]  A. Levin,et al.  Harmonizing Acute and Chronic Kidney Disease Definition and Classification: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. , 2021, Kidney international.

[4]  L. Forni,et al.  Recommendations on Acute Kidney Injury Biomarkers From the Acute Disease Quality Initiative Consensus Conference: A Consensus Statement. , 2020, JAMA network open.

[5]  C. Ross,et al.  Epidemiologic Characteristics of Acute Kidney Injury During Cisplatin Infusions in Children Treated for Cancer , 2020, JAMA network open.

[6]  C. Kovesdy,et al.  Iron Deficiency in Chronic Kidney Disease: Updates on Pathophysiology, Diagnosis, and Treatment. , 2020, Journal of the American Society of Nephrology : JASN.

[7]  C. R. Leemans,et al.  Incidence and risk factors for acute kidney injury in head and neck cancer patients treated with concurrent chemoradiation with high-dose cisplatin , 2019, BMC Cancer.

[8]  J. Buatti,et al.  Phase IIb, Randomized, Double-Blind Trial of GC4419 Versus Placebo to Reduce Severe Oral Mucositis Due to Concurrent Radiotherapy and Cisplatin For Head and Neck Cancer , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  R. Haddad,et al.  Best Practice in Systemic Therapy for Head and Neck Squamous Cell Carcinoma , 2019, Front. Oncol..

[10]  R. Jankovic,et al.  Elevated Serum Ferritin Levels Are Predictive of Renal Function Recovery among Patients with Acute Kidney Injury. , 2019, Tohoku journal of experimental medicine.

[11]  D. Holanda,et al.  Persistent increase in mitochondrial superoxide mediates cisplatin-induced chronic kidney disease , 2018, Redox biology.

[12]  R. Arora,et al.  Early intraoperative iron‐binding proteins are associated with acute kidney injury after cardiac surgery , 2019, The Journal of thoracic and cardiovascular surgery.

[13]  D. Swinkels,et al.  Tubular iron deposition and iron handling proteins in human healthy kidney and chronic kidney disease , 2018, Scientific Reports.

[14]  D. Spitz,et al.  Superoxide Dismutase Mimetic GC4419 Enhances the Oxidation of Pharmacological Ascorbate and Its Anticancer Effects in an H2O2-Dependent Manner , 2018, Antioxidants.

[15]  J. Carcillo,et al.  Hyperferritinemia and inflammation , 2017, International immunology.

[16]  J. Buatti,et al.  Mitochondrial Superoxide Increases Age-Associated Susceptibility of Human Dermal Fibroblasts to Radiation and Chemotherapy. , 2017, Cancer research.

[17]  Christie P. Thomas,et al.  EGF regulation of proximal tubule cell proliferation and VEGF‐A secretion , 2017, Physiological reports.

[18]  D. Majid,et al.  Tumor necrosis factor-α, kidney function, and hypertension. , 2017, American journal of physiology. Renal physiology.

[19]  P. Wee,et al.  Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways , 2017, Cancers.

[20]  R. Bellomo,et al.  Acute kidney disease and renal recovery: consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup , 2017 .

[21]  C. Ross,et al.  Design and Methods of the Pan-Canadian Applying Biomarkers to Minimize Long-Term Effects of Childhood/Adolescent Cancer Treatment (ABLE) Nephrotoxicity Study , 2017, Canadian journal of kidney health and disease.

[22]  R. Bellomo,et al.  Dialysis: Efficacy of tenapanor in hyperphosphataemia , 2017, Nature Reviews Nephrology.

[23]  R. Gansevoort,et al.  The epidermal growth factor receptor pathway in chronic kidney diseases , 2016, Nature Reviews Nephrology.

[24]  S. Mehta,et al.  Long-Term Renal Outcomes after Cisplatin Treatment. , 2016, Clinical journal of the American Society of Nephrology : CJASN.

[25]  B. Ratliff,et al.  Oxidant Mechanisms in Renal Injury and Disease. , 2016, Antioxidants & redox signaling.

[26]  G. Yoo,et al.  Understanding the Risk Factors and Long-Term Consequences of Cisplatin-Associated Acute Kidney Injury: An Observational Cohort Study , 2015, PloS one.

[27]  C. Krawczeski,et al.  Association of definition of acute kidney injury by cystatin C rise with biomarkers and clinical outcomes in children undergoing cardiac surgery. , 2015, JAMA pediatrics.

[28]  P. Kimmel,et al.  Acute kidney injury and chronic kidney disease as interconnected syndromes. , 2014, The New England journal of medicine.

[29]  Douglas B Kell,et al.  Serum ferritin is an important inflammatory disease marker, as it is mainly a leakage product from damaged cells. , 2014, Metallomics : integrated biometal science.

[30]  D. Ilatovskaya,et al.  Epidermal growth factors in the kidney and relationship to hypertension. , 2013, American journal of physiology. Renal physiology.

[31]  Brian J. Smith,et al.  Ketogenic Diets Enhance Oxidative Stress and Radio-Chemo-Therapy Responses in Lung Cancer Xenografts , 2013, Clinical Cancer Research.

[32]  J. Garvin,et al.  Tumor necrosis factor-α: regulation of renal function and blood pressure. , 2013, American journal of physiology. Renal physiology.

[33]  Jian-Kang Chen,et al.  Deletion of the epidermal growth factor receptor in renal proximal tubule epithelial cells delays recovery from acute kidney injury , 2012, Kidney international.

[34]  G. Ramesh,et al.  Mechanisms of Cisplatin Nephrotoxicity , 2010, Toxins.

[35]  F. Torti,et al.  Serum ferritin: Past, present and future. , 2010, Biochimica et biophysica acta.

[36]  L. Stevens,et al.  Estimating GFR using the CKD Epidemiology Collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions. , 2010, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[37]  S. Stancu,et al.  Bone marrow iron, iron indices, and the response to intravenous iron in patients with non-dialysis-dependent CKD. , 2010, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[38]  Jong-Hyuk Lee,et al.  Ferritin binds and activates p53 under oxidative stress. , 2009, Biochemical and biophysical research communications.

[39]  F. Torti,et al.  Ferritin for the clinician. , 2009, Blood reviews.

[40]  D. Bolignano,et al.  Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[41]  P. Arosio,et al.  New functions for an iron storage protein: the role of ferritin in immunity and autoimmunity. , 2008, Journal of autoimmunity.

[42]  E. Neilson,et al.  Chronic kidney disease progression. , 2006, Journal of the American Society of Nephrology : JASN.

[43]  A. Phillips.  The role of renal proximal tubular cells in diabetic nephropathy , 2003, Current diabetes reports.

[44]  K. Decker.  [Tumor necrosis factor alpha]. , 1992, Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis.